Zacks Investment Research upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a hold rating to a buy rating in a research report released on Wednesday, Zacks.com reports. The brokerage currently has $5.25 target price on the stock.
According to Zacks, “PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company’s products are based on the proprietary Versamune(R) platform technology, which activates and directs the human immune system. PDS Biotechnology Corp, formerly known as Edge Therapeutics Inc., is based in Berkeley Heights, United States. “
Other analysts have also issued research reports about the company. Oppenheimer reissued a buy rating and issued a $7.00 target price on shares of PDS Biotechnology in a report on Thursday, March 11th. HC Wainwright upped their target price on PDS Biotechnology from $6.00 to $8.00 and gave the company a buy rating in a report on Thursday, March 25th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $7.23.
PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Thursday, March 18th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. On average, equities research analysts anticipate that PDS Biotechnology will post -0.9 earnings per share for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of PDSB. BlackRock Inc. boosted its stake in shares of PDS Biotechnology by 624.5% during the third quarter. BlackRock Inc. now owns 104,415 shares of the company’s stock valued at $244,000 after acquiring an additional 90,002 shares during the last quarter. Ellis Investment Partners LLC boosted its stake in shares of PDS Biotechnology by 693.3% during the fourth quarter. Ellis Investment Partners LLC now owns 17,850 shares of the company’s stock valued at $38,000 after acquiring an additional 15,600 shares during the last quarter. Newman & Schimel LLC acquired a new stake in shares of PDS Biotechnology during the fourth quarter valued at $25,000. Minot Wealth Management LLC acquired a new stake in shares of PDS Biotechnology during the fourth quarter valued at $105,000. Finally, Renaissance Technologies LLC boosted its stake in shares of PDS Biotechnology by 5.7% during the fourth quarter. Renaissance Technologies LLC now owns 828,721 shares of the company’s stock valued at $1,773,000 after acquiring an additional 44,864 shares during the last quarter. 14.80% of the stock is currently owned by institutional investors and hedge funds.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
Recommended Story: Street Name
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.